News | August 08, 2021
Cipla posts net profit at Rs 715 crores
India business contributes to a stellar performance
India business contributes to a stellar performance
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
Subscribe To Our Newsletter & Stay Updated
